Thus, in the case of TNFR2-expressing tumor cells, TNFR2 agonists may not only improve TNF release by CD8+ T-cells, but may also sensitize the tumor cells for TNF-induced cell death. This evidence concerns the gene TNFRSF1B and neoplasm.